FibroGen has been granted a patent for a method and compounds that regulate erythropoiesis and iron metabolism, treating anemia and iron deficiency in patients with kidney disease. GlobalData’s report on FibroGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on FibroGen, human telomerase RT biomarker was a key innovation area identified from patents. FibroGen's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating anemia in kidney disease with compound formula (i)
A recently granted patent (Publication Number: US11680047B2) discloses a method for treating anemia in human subjects with kidney disease. The method involves administering a compound of formula (I) to the subjects. The compound is capable of inhibiting the activity of the hypoxia-inducible factor (HIF) prolyl hydroxylase enzyme and stabilizing the alpha subunit of hypoxia-inducible factor.
The compound can be orally administered to the subjects, and it is effective in both subjects undergoing kidney dialysis and those not undergoing dialysis. Following administration of the compound, there is an increase in the levels of erythropoietin plasma, plasma hematocrit, and plasma hemoglobin in the subjects. This suggests that the compound has a positive effect on the production of red blood cells, which is beneficial for treating anemia.
Furthermore, the administration of the compound reduces the need for the subjects to receive allogenic blood transfusions, which can be a significant advantage in managing anemia in kidney disease patients. In some embodiments, the method also involves administering exogenous erythropoietin to the subjects, which can further enhance the treatment of anemia.
The patent also covers the treatment of anemia in human subjects with chronic renal failure using the same compound of formula (I). The method and its effectiveness are similar to those described for subjects with kidney disease.
Overall, this granted patent presents a method for treating anemia in human subjects with kidney disease or chronic renal failure. The method involves administering a specific compound that inhibits the HIF prolyl hydroxylase enzyme and stabilizes the alpha subunit of HIF. The compound can be orally administered and has shown to increase erythropoietin plasma levels, plasma hematocrit, and plasma hemoglobin levels in the subjects. Additionally, the method reduces the need for allogenic blood transfusions and can be combined with exogenous erythropoietin administration for enhanced treatment.
To know more about GlobalData’s detailed insights on FibroGen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
